New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
12:31 EDTCLMT, SONC, ZIOP, BRK.A, RFMD, GSOn The Fly: Midday Wrap
Stocks on Wall Street were higher right out of the gate and have not moved far from their opening levels near midday. Investors received a fair amount of domestic economic data, including better than expected reports on home prices and durable goods orders. The flip side, however, was some worse than expected consumer confidence and new home sales data. Despite the mixed data, the market seems intent on closing the quarter with its gains intact as the end of the month approaches... ECONOMIC EVENTS: In the U.S., overall orders for durable goods rose 5.7% in February, versus expectations for an increase of 3.9%. However, excluding transportation, orders slipped 0.5%, versus expectations for a 0.6% rise. The S&P/Case-Shiller 20-city home price index climbed 8.1% in the 12 months ending in January, after rising 6.8% a month earlier. New home sales dropped 4.6% to 411K in February, versus expectations for a decline to 414K. Consumer confidence fell 8.3 points to 59.7 in March, which was worse than the expected pull back to 69.0. The Richmond Fed manufacturing survey reading of 3 for March missed expectations for it to hold at 6... COMPANY NEWS: Goldman Sachs (GS) announced that it amended its warrant agreement with Berkshire Hathaway (BRK.A) to settle in terms of net shares in place of a cash settlement, quoting Berkshire's Chairman and CEO Warren Buffett as having said, "We intend to hold a significant investment in Goldman Sachs." Shares of Goldman, which rose early in the session, were down fractionally near noon... MAJOR MOVERS: Among the notable gainers were Sonic (SONC), which rose 8% following its earnings report, and RF Micro Devices (RFMD), which rallied nearly 6% after Oppenheimer upgraded the stock to an Outperform rating. Among the noteworthy losers was Ziopharm (ZIOP), which was downgraded by at least four analyst firms and plunged over 61% after terminating development of a cancer drug after a clinical study missed its goal. Also lower were shares of Calumet Specialty Products (CLMT), down 4% after an offering of 5.25M of its shares priced at $37.50... INDICES: Near midday, the Dow was up 74.84, or 0.52%, to 14,522.59; the Nasdaq was up 5.90, or 0.18%, to 3,241.20; and the S&P 500 was up 6.36, or 0.41%, to 1,558.05.
News For A;SONC;RFMD;ZIOP;CLMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
16:00 EDTAOptions Update; November 24, 2015
iPath S&P 500 VIX Short-Term Futures up 13c to 19.04, Option volume leaders: AAPL FB NFLX BAC PFE AMZN CHK TWTR GE SUNE DE AGN AAL MSFT INTC X BABA A
15:38 EDTAOptions with increasing volume: SUNE HPQ TSM PMCS TSO EPI A DE CREE
November 23, 2015
10:00 EDTCLMTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adesto Technologies (IOTS) initiated with a Buy at Roth Capital... American Farmland (AFCO) initiated with an Outperform at Oppenheimer... Blackstone (BX) initiated with a Neutral at JPMorgan... California Resources (CRC) initiated with a Buy at Ladenburg... Calumet Specialty Products (CLMT) initiated with a Neutral at Goldman... Clearfield (CLFD) initiated with a Buy at Lake Street... Coherus Biosciences (CHRS) initiated with an Overweight at Barclays... Copa Holdings (CPA) initiated with a Buy at HSBC... GOL Linhas (GOL) initiated with a Reduce at HSBC... HP Enterprise (HPE) initiated with a Hold at Maxim... Himax (HIMX) initiated with an Overweight at Morgan Stanley... Horizon Pharma (HZNP) reinstated with a Buy at Jefferies... Match Group (MTCH) initiated with a Buy at Axiom... Mirati Therapeutics (MRTX) initiated with a Neutral at Citi... Momenta (MNTA) initiated with an Equal Weight at Barclays... MyoKardia (MYOK) initiated with an Outperform at Cowen... Revance (RVNC) initiated with a Buy at Guggenheim.
06:31 EDTCLMTCalumet Specialty Products initiated with a Neutral at Goldman
Subscribe for More Information
November 19, 2015
16:10 EDTAAgilent increases cash dividend to 11.5c per share
Subscribe for More Information
07:07 EDTZIOPZIOPHARM announces data highlighting Ad-RTS-hIL-12 activity in Glioma
ZIOPHARM Oncology announced that the company is presenting initial results from an ongoing Phase 1 dose-escalation study of Ad-RTS-hIL-12 + orally administered veledimex in recurrent or progressive glioblastoma or grade III malignant glioma. The presentation, titled "Intratumoral Regulated Expression of IL-12 as a Gene Therapy Approach to Treatment of Glioma," will be delivered at 5:15 pm CT, Saturday, November 21, 2015 at the 20th Annual Society for Neuro-Oncology, or SNO, Annual Scientific Meeting in San Antonio, Texas. Ad-RTS-hIL-12 + the oral activator veledimex is a novel viral gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T-cell immune response. The ongoing multi-center Phase 1 trial of Ad-RTS-hIL-12 + veledimex examines a gene therapy strategy for recurrent high grade gliomas, with the goal of generating a localized anti-tumor immune response. The primary objective of the study is to determine the safety and tolerability of a single intra-tumoral Ad-RTS-hIL-12 injection activated upon dosing with oral veledimex. Secondary objectives are to determine the Ad-RTS-hIL-12 + veledimex maximum tolerated dose, the immune responses elicited by Ad-RTS-hIL-12 + veledimex, and assessment of biologic response. The study is expected to enroll up to 72 subjects. Preclinically, the effects of Ad-RTS-mIL-12 + veledimex were studied in orthotopic glioma animal models, demonstrating veledimex crossed the blood-brain-barrier. In a standard orthotopic glioma mouse model that evaluated dexamethasone, bevacizumab, temozolamide and a PD-1 inhibitor, Ad-RTS-mIL-12 + veledimex demonstrated a dramatic dose-related increase in survival, without significant adverse events, that was superior to all other treatments. In the current, on-going Phase 1 study, five patients are available for initial assessment, two with recurrent grade III malignant glioma and three with grade IV. Results show IL-12 was detectable in peripheral blood along with downstream IFNg, indicating that veledimex crossed the blood brain barrier activating IL-12 expression from intra-tumorally administered Ad-RTS-hIL-12. Ad-RTS-hIL-12 + veledimex was well tolerated with minimal neurologic toxicity. The most common adverse events were headache, fever, hyponatremia and nausea/vomiting. Related serious adverse events were aseptic meningitis, neutropenia, thrombocytopenia, leukopenia, with all toxicity to date consistent with the "on-target" effects of immunotherapy.
November 18, 2015
08:14 EDTCLMTRBC Capital to hold a conference
Subscribe for More Information
07:49 EDTSONCStephens to host a tour
Subscribe for More Information
November 17, 2015
08:43 EDTAAgilent pullback after earnings a buying opportunity, says Cowen
Cowen said any pullback in Agilent after its Q4 earnings report would be a buying opportunity. Even though guidance was lower than expected, the firm still thinks 2017 targets are achievable. Cowen maintained its Market Perform rating and $39 price target on Agilent shares.
November 16, 2015
18:26 EDTAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Nuance (NUAN), up 9.5%. ALSO HIGHER: Ocera Therapeutics (OCRX), up 26.6% after announcing Phase 1 study results for the company's oral formulation of OCR-002. DOWN AFTER EARNINGS: Urban Outfitters (URBN), down 11.5%... Agilent (A), down 1.3%. ALSO LOWER: Wayfair (W), down 2% after Bloomberg reported that Whitney Tilson said that Wayfair is currently his largest short.
16:10 EDTAAgilent reports Q4 LSAG revenue down 4% to $515M
Subscribe for More Information
16:09 EDTAAgilent sees FY16 adjusted EPS $1.85-$1.91, consensus $1.97
Sees FY16 revenue $4.15B-$4.17B, consensus $4.21B.
16:08 EDTAAgilent sees Q1 adjusted EPS 42c-44c, consensus 47c
Subscribe for More Information
16:07 EDTAAgilent reports Q4 adjusted EPS 50c, consensus 47c
Subscribe for More Information
15:02 EDTANotable companies reporting after market close
Subscribe for More Information
07:54 EDTCLMTCalumet Specialty Products coverage resumed with an Outperform at RBC Capital
Target $32.
06:22 EDTCLMTCalumet Specialty Products initiated with a Buy at DA Davidson
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use